Breasthealth UK (BHUK) and Lab21 have established a partnership to offer UK women state-of-the-art personalised health management and predictive genetic testing for breast cancer risk.
Lab21 is a private clinical diagnostic service company that maintains a comprehensive breast cancer diagnostic portfolio.
It has brought together a range of tests to accurately measure predisposition to breast cancer and to optimise treatment options in patients diagnosed with breast disease.
Many of these tests, such as the Decode Breastcancer assay and the Myriad assays, are available in the UK through Lab21.
BHUK offers personalised, private breast screening services.
The partnership with Lab21 provides patients with laboratory diagnostic services to support the expanding portfolio of diagnostic and breast screening services.
Breasthealth UK is launching an approach to screening called the Breast Health Risk Assessment Service.
The Decode Breastcancer test, which has been validated in more than 100,000 women, will be offered as part of an overall breast cancer risk assessment that takes into account family history and lifestyle factors using the Tyrer-Cuzick model.
Results will be provided in consultation with an experienced breast surgeon to interpret the results and recommend potential follow-up breast screening as required.
The Myriad BRCA1 and BRCA2 genetic tests are suitable for women with a strong family history of breast cancer.
Specialist counselling is provided to support women that require this test.
The Myriad BRCA tests are based on extensive clinical research and are currently the only tests available that address predisposition to familial (inherited) breast cancer.
'Our aim is to offer appropriate and timely breast screening to women of all ages, to ensure that breast cancer or other problems are identified and treated early,' said Troels Jordansen, chief executive officer of Breasthealth UK.
BHUK works in close cooperation with Spire Healthcare and is expanding the number of clinics in the UK via the Spire hospital network to provide nationwide access to its screening programme.
